Analyst Justin Walsh of JonesTrading reiterated a Buy rating on TFF Pharmaceuticals (TFFP – Research Report), reducing the price target to $4.00.
Justin Walsh has given his Buy rating due to a combination of factors, including the ongoing progress of TFF Pharmaceuticals’ lead asset, TFF TAC, and the underlying potential of the company’s formulation technology. The Phase II trial for TFF TAC, aimed at preventing organ rejection in lung transplant patients, is actively enrolling and showing promise with patients opting to continue in the safety extension phase. The company’s strategic focus on the development of this asset and the search for partnership opportunities for another product, TFF VORI, are also pivotal considerations in this assessment.
Moreover, despite the reduction in the price target from $13 to $4, Walsh maintains a positive outlook based on the strong clinical data and significant market opportunity for TFF TAC. The favorable pharmacokinetic analysis, absence of acute rejection incidents, and lower required dosage compared to oral administration highlight the drug’s potential efficacy and safety profile. These factors, along with anticipated feedback from the FDA and the prospect of securing partners or funding, contribute to Walsh’s confidence in the stock’s performance.
Walsh covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Perspective Therapeutics, and Vor Biopharma. According to TipRanks, Walsh has an average return of 3.4% and a 38.56% success rate on recommended stocks.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
TFF Pharmaceuticals (TFFP) Company Description:
TFF Pharmaceuticals, Inc. operates as an early-stage biopharmaceutical company. It develops and commercializes drug products based on its Thin film Freezing (TFF) technology platform. The firm also engages in research, development & drug formulation and initial testing of drug products. The company was founded in 2005 and is headquartered in Toronto, Canada.
Read More on TFFP:
- TFF Pharmaceuticals provides update on TFF TAC Phase 2 trial
- TFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering
- TFF Pharmaceuticals 1.67M share Secondary priced at $2.88
- TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering
- TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting
